MARKET

PTN

PTN

Palatin Tech
AMEX
1.820
0.000
0.00%
Opening 15:52 04/16 EDT
OPEN
1.865
PREV CLOSE
1.820
HIGH
1.910
LOW
1.810
VOLUME
231.90K
TURNOVER
0
52 WEEK HIGH
5.65
52 WEEK LOW
1.430
MARKET CAP
29.37M
P/E (TTM)
-0.7344
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PTN last week (0408-0412)?
Weekly Report · 1d ago
Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying
Insider transactions for penny stocks indicate confidence or concern around the company's prospects. Augusta Gold Corp. And Tecogen Inc. Are two companies with recent notable insider transactions. The Dow Jones index closed slightly lower on Thursday. Palatin Technologies, Inc. And Augusta Gold Corporation are among the recent penny stocks with notable insider trades.
Benzinga · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-JPMorgan, Ameresco, Copper miners
Wall Street's main stock indexes advanced in choppy trading on Monday. The Dow Jones Industrial Average was up 0.10% at 38,941.91. The top three S&P 500 percentage gainers were Tesla, GE and Ameresco. Treasury yields retreated from session highs as investors awaited the Fed's rate outlook.
Reuters · 04/08 16:11
Buy Rating Affirmed for Palatin Technologies Following Successful Phase 3 Trial of PL9643 for Dry Eye Disease
TipRanks · 04/08 15:05
Palatin Technologies Shares Rise 27% After Positive Trial Results for PL9643
Palatin Technologies shares were up 27% to $2.24. The company said it saw positive topline results for its Phase 3 pivotal clinical trial. The stock hit its 52-week high of $5.65 on Jan. 29. Palatin said the study demonstrated positive results for dry eye disease treatment.
Dow Jones · 04/08 14:46
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
Palatin Technologies Inc. Announced topline results for its Phase 3 dry eye disease trial. The company says PL9643 has a superior safety and tolerability profile. Dry eye disease is one of the most common ocular disorders in the U.S. The dry eye market is estimated to be $6.11 billion.
Benzinga · 04/08 14:02
Palatin stock jumps 16% on positive Phase 3 data for eye drug
Palatin stock jumps 16% on positive Phase 3 data for eye drug for dry eye disease. Palatin Technologies reported positive data for its drug candidate PL9643 in the treatment of dry eye diseases. The company is in talks with potential partners for the product, Palatin says.
Seeking Alpha · 04/08 13:49
Microstrategy, Apartment Income REIT, Marathon Digital among premarket gainers' pack
Microstrategy, Apartment Income REIT, Marathon Digital among premarket gainers' pack. Auddia AUUD +123% on bagging a U.S. Patent for the core AI technology it uses in its radio app. Bitcoin again surpassed the $72,000 level.
Seeking Alpha · 04/08 13:10
More
About PTN
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also engaged developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. It has completed Phase III PL9643 clinical study for dry eye disease. It is also conducting Phase II study of oral PL8177 in patients with ulcerative colitis.

Webull offers Palatin Technologies, Inc. stock information, including AMEX: PTN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTN stock methods without spending real money on the virtual paper trading platform.